What is Scout Bio?
Scout Bio is a pioneering biotechnology firm dedicated to revolutionizing pet medicine by developing one-time gene therapies and monoclonal antibodies. By utilizing advanced AAV vector technology, the company enables the long-term expression of therapeutic proteins, effectively targeting chronic diseases that have historically lacked viable treatment options. Through a strategic partnership with the University of Pennsylvania's Gene Therapy Program, Scout Bio bridges the gap between human-grade medical innovation and veterinary care. The company serves a critical market need, providing veterinary professionals and pet owners with sophisticated, durable solutions that improve the standard of care for animals suffering from complex, long-term health challenges.
How much funding has Scout Bio raised?
Scout Bio has raised a total of $62.3M across 2 funding rounds:
Series A
$9.3M
Series B
$53M
Series A (2018): $9.3M with participation from Frazier Healthcare Partners
Series B (2021): $53M led by RiverVest Venture Partners, Digitalis Ventures, Frazier Healthcare Partners, and OrbiMed
Key Investors in Scout Bio
RiverVest Venture Partners
RiverVest is a prominent venture capital firm focused on building life science companies to meet significant unmet medical needs, supporting entrepreneurs through a commitment to science and innovation.
Digitalis Ventures
Digitalis Ventures engineers solutions to unmet needs in health by leveraging deep technical and domain expertise, focusing on scaling enterprises that improve human and animal health.
OrbiMed
OrbiMed is a specialized investment firm focused on the healthcare sector, managing capital across biopharmaceuticals and medical devices with a deep expertise in life sciences innovation.
What's next for Scout Bio?
With the recent capital injection, Scout Bio is poised to transition from its foundational research phase into a more aggressive commercialization and clinical validation stage. The strategic focus will likely center on scaling its manufacturing capabilities for AAV-based therapies and expanding its portfolio of therapeutic candidates. As the company continues to refine its platform, it will likely prioritize regulatory milestones and the establishment of broader distribution channels within the veterinary medical community. This phase of development is critical for validating the long-term efficacy of its gene therapy approach, potentially setting a new benchmark for how chronic conditions are managed in the companion animal market.
See full Scout Bio company page
